aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma (NASDAQ: ATYR), a clinical-stage biotech company, has granted stock options to two new employees as part of their inducement compensation package. The options allow the purchase of 36,200 shares of common stock at $3.00 per share, matching the closing price on May 15, 2025. These grants, made under the aTyr Pharma 2022 Inducement Plan, follow Nasdaq Listing Rule 5635(c)(4).
The options vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over three years, contingent on continued employment. aTyr focuses on developing first-in-class medicines from its tRNA synthetase platform, with their lead candidate efzofitimod targeting interstitial lung disease treatment.
aTyr Pharma (NASDAQ: ATYR), un'azienda biotecnologica in fase clinica, ha assegnato opzioni su azioni a due nuovi dipendenti come parte del loro pacchetto di compensazione incentivante. Le opzioni consentono l'acquisto di 36.200 azioni ordinarie a 3,00 $ per azione, corrispondenti al prezzo di chiusura del 15 maggio 2025. Questi conferimenti, effettuati secondo il Piano di Induzione aTyr Pharma 2022, rispettano la Regola Nasdaq 5635(c)(4).
Le opzioni maturano in un periodo di quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura mensilmente nei successivi tre anni, subordinatamente alla continuazione del rapporto di lavoro. aTyr si concentra sullo sviluppo di farmaci innovativi basati sulla sua piattaforma di sintasi tRNA, con il candidato principale efzofitimod rivolto al trattamento delle malattie polmonari interstiziali.
aTyr Pharma (NASDAQ: ATYR), una empresa biotecnológica en fase clínica, ha otorgado opciones sobre acciones a dos nuevos empleados como parte de su paquete de compensación por inducción. Las opciones permiten la compra de 36,200 acciones ordinarias a 3.00 $ por acción, igualando el precio de cierre del 15 de mayo de 2025. Estas concesiones, realizadas bajo el Plan de Inducción aTyr Pharma 2022, cumplen con la Norma Nasdaq 5635(c)(4).
Las opciones se consolidan durante cuatro años, con un 25% consolidado después de un año y el 75% restante consolidándose mensualmente durante los siguientes tres años, condicionado a la continuidad laboral. aTyr se enfoca en desarrollar medicamentos innovadores a partir de su plataforma de sintetasas de tRNA, con su principal candidato efzofitimod dirigido al tratamiento de enfermedades pulmonares intersticiales.
aTyr Pharma (NASDAQ: ATYR)는 임상 단계의 바이오테크 기업으로, 두 명의 신규 직원에게 유인 보상 패키지의 일환으로 스톡 옵션을 부여했습니다. 이 옵션은 2025년 5월 15일 종가인 주당 3.00달러에 36,200주의 보통주를 매수할 수 있는 권리입니다. 이 부여는 aTyr Pharma 2022 유인 계획에 따라 이루어졌으며, 나스닥 상장 규칙 5635(c)(4)를 준수합니다.
옵션은 4년에 걸쳐 베스팅되며, 1년 후 25%가 베스팅되고 나머지 75%는 3년 동안 매월 베스팅되며, 계속 근무 조건이 붙습니다. aTyr는 tRNA 합성효소 플랫폼을 기반으로 한 혁신적인 신약 개발에 집중하고 있으며, 주요 후보물질인 efzofitimod는 간질성 폐질환 치료를 목표로 하고 있습니다.
aTyr Pharma (NASDAQ: ATYR), une entreprise biotechnologique en phase clinique, a accordé des options d'achat d'actions à deux nouveaux employés dans le cadre de leur package de rémunération incitative. Ces options permettent l'achat de 36 200 actions ordinaires au prix de 3,00 $ par action, correspondant au cours de clôture du 15 mai 2025. Ces attributions, effectuées dans le cadre du Plan d'Induction aTyr Pharma 2022, respectent la règle Nasdaq 5635(c)(4).
Les options se acquièrent sur une période de quatre ans, avec 25 % acquises après un an et les 75 % restants acquis mensuellement sur les trois années suivantes, sous réserve de la poursuite de l'emploi. aTyr se concentre sur le développement de médicaments de première classe issus de sa plateforme de synthétases d'ARNt, avec pour principal candidat efzofitimod ciblant le traitement des maladies pulmonaires interstitielles.
aTyr Pharma (NASDAQ: ATYR), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, hat zwei neuen Mitarbeitern im Rahmen ihres Anreizvergütungspakets Aktienoptionen gewährt. Die Optionen ermöglichen den Kauf von 36.200 Aktien zum Preis von 3,00 $ pro Aktie, entsprechend dem Schlusskurs vom 15. Mai 2025. Diese Zuteilungen erfolgen gemäß dem aTyr Pharma 2022 Inducement Plan und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
Die Optionen werden über vier Jahre vestet, wobei 25 % nach einem Jahr und die restlichen 75 % monatlich über drei Jahre vesten, vorausgesetzt die Beschäftigung wird fortgesetzt. aTyr konzentriert sich auf die Entwicklung von First-in-Class-Medikamenten basierend auf seiner tRNA-Synthetase-Plattform, wobei der Hauptkandidat efzofitimod die Behandlung von interstitiellen Lungenerkrankungen anstrebt.
- None.
- None.
SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 36,200 shares of aTyr’s common stock, each with an exercise price of
Each option vests over a period of four years, with
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
What stock options did aTyr Pharma (ATYR) grant to new employees in May 2025?
What is the vesting schedule for aTyr Pharma's (ATYR) May 2025 employee stock options?
What is aTyr Pharma's (ATYR) main business focus?
What is efzofitimod and what is it being developed for by aTyr Pharma (ATYR)?
